Screening Male BRCA Mutation Carriers: Effectiveness of Multispectral 3T Magnetic Resonance Imaging
Men with a BRCA1 or BRCA2 mutation are at increased risk for early onset, aggressive
prostate cancer compared to men in the general population.
Standard of care screening for men with a BRCA mutation includes PSA testing and digital
rectal examination (DRE), the same as with men in the general population.
This study is being done to assess whether there is value in using MRI as a screening tool
to detect prostate cancer at an earlier stage than may otherwise be detected using standard
of care screening (PSA, DRE). It is unclear whether MRI has utility as a screening tool in
this specific population at high risk for aggressive disease.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society